2023-504896-26-00RecruitingPhase 1
A Phase 1 Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
Janssen - Cilag International3 sites in 1 country80 target enrollmentStarted: January 9, 2024Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 80
- Locations
- 3
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CTIS Point of Contact
Scientific
Janssen - Cilag International
Study Sites (3)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase 1 Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid TumorsAdvanced Stage Solid TumorsCTIS2023-504896-26-00Janssen - Cilag International80
Recruiting
Phase 1
A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer2023-504063-17-00Janssen - Cilag International48
Completed
Phase 1
A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia2024-512689-32-00Janssen Cilag International12
Recruiting
Phase 1
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and ApixabanNCT07265466Onconic Therapeutics Inc.96
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07258511Janssen Research & Development, LLC400